ALPE participates in FDA Advisory Committees meeting on achondroplasia

Two of FDA Advisory Committees: the Pediatric Advisory Committee and the Endocrinologic

Read more ...

Ascendis Pharma starts Phase 1 Trial of TransCon CNP for achondroplasia

On the 8th May 2018, Ascendis Pharma announced the dosing of the first subjects 

Read more ...

ALPE wins the 10th Social Projects of Santander Bank call

The ALPE Foundation was awarded in the 10th Call for Social Projects of the Santander Group.

Read more ...

Request of participation for an international study on Achondroplasia

The Brod Group, is science-based health outcomes research group are looking for participants living in the USA

Read more ...

Study reveals new information on obesity in achondroplasia and the soluble FGFR3

A recent study by Celine Saint-Laurent, Stephanie Garcia and

Read more ...

European Pillar of Social Rights

The European Pillar of Social Rights sets the basis and framework for a fairer and more inclusive Europe.

Read more ...

Call for the 4th ALPE Awards

We are pleased to announce the 4th ALPE Awards 2018 for the best work

Read more ...

BioMarin starts LIAISE study on achondroplasia

In November 2017, BioMarin shared an update for Associations and Families on achondroplasia

Read more ...

A new clinical trial starts for achondroplasia

Therachon announced on the 14th February 2018 to have started the phase 1 of the clinical trial for TA-46.

Read more ...